4-Oxo-1,4-dihydropyridines as selective CB2 cannabinoid receptor ligands: structural insights into the design of a novel inverse agonist series.
Growing evidence shows that CB(2) receptor is an attractive therapeutic target. Starting from a series of 4-oxo-1,4-dihydroquinoline-3-carboxamide as selective CB(2) agonists, we describe here the medicinal chemistry approach leading to the development of CB(2) receptor inverse agonists with a 4-oxo-1,4-dihydropyridine scaffold. The compounds reported here show high affinity and potency at the CB(2) receptor while showing only modest affinity for the centrally expressed CB(1) cannabinoid receptor. Further, we found that the functionality of this series is controlled by its C-6 substituent because agonists bear a methyl or a tert-butyl group and inverse agonists, a phenyl or 4-chlorophenyl group, respectively. Finally, in silico studies suggest that the C-6 substituent could modulate the conformation of W6.48 known to be critical in GPCR activation.
Université Lille-Nord de France, Institut de Chimie Pharmaceutique Albert Lespagnol, EA 2692, IFR 114, 3 Rue du Professeur Laguesse, BP 83, 59006 Lille Cedex, France.
Jamal
J
El Bakali
Giulio G
GG
Muccioli
Nicolas
N
Renault
Delphine
D
Pradal
Mathilde
M
Body-Malapel
Madjid
M
Djouina
Laurie
L
Hamtiaux
Virginie
V
Andrzejak
Pierre
P
Desreumaux
Philippe
P
Chavatte
Didier M
DM
Lambert
Régis
R
Millet
D000595:Amino Acid Sequence; D000818:Animals; D016466:CHO Cells; D006224:Cricetinae; D003412:Cricetulus; D004095:Dihydropyridines / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D054314:Drug Inverse Agonism; D006801:Humans; D008024:Ligands; D008958:Models, Molecular; D008969:Molecular Sequence Data; D011869:Radioligand Assay; D043885:Receptor, Cannabinoid, CB2 / Q000819:agonists / Q000037:antagonists & inhibitors*; D016415:Sequence Alignment; D013237:Stereoisomerism; D013329:Structure-Activity Relationship
D004095:Dihydropyridines; D008024:Ligands; D043885:Receptor, Cannabinoid, CB2